Shows
CME in Minutes: Education in OphthalmologyNancy M. Holekamp, MD - Eyeing the Benefits and Risks of VEGF-Targeted Therapies for nAMDPlease visit answersincme.com/BJH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in retinal disease discusses strategies for treating patients with intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of available intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration (nAMD); Outline practical strategies to individualize intravitreal VEGF-targeted treatment selection and dosing for patients with nAMD; and Describe management strategies to optimize outcomes for patients receiving intravitreal VEGF-targeted therapy for nAMD.2023-01-0514 min
Keeping the Well in Well-thyNavigating Aging Eye Care with Dr. Nancy HolekampIf you have trouble seeing, have constant dry eyes, if you are wondering if everyone gets cataracts or sunglasses and finally, if you are wondering how vitamins can maintain the overall health of your eyes, this episode is for you! In this episode, Barbara Archer is joined by Dr. Nancy Holekamp, director of retina services at the Pepose Vision Institute in St. Louis. Dr. Holekamp is an international speaker, consultant to numerous ophthalmic pharmaceutical companies, and was previously a professor of clinical ophthalmology and visual sciences at the Washington School of Medicine. She received her bachelor degree w...2022-11-0933 min
CME in Minutes: Education in Primary CareNancy M. Holekamp, MD - Eyeing the Benefits and Risks of VEGF-Targeted Therapies for nAMDPlease visit answersincme.com/BJH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in retinal disease discusses strategies for treating patients with intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of available intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration (nAMD); Outline practical strategies to individualize intravitreal VEGF-targeted treatment selection and dosing for patients with nAMD; and Describe management strategies to optimize outcomes for patients receiving intravitreal VEGF-targeted therapy for nAMD.2022-09-0114 min
MedEdTalks - OphthalmologyTargeting Angiopoietin-2 in DME: Efficacy and Safety Data With Drs. Carl Regillo and Nancy HolekampThe angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this p...2022-05-3116 min
Retina SynthesisHome OCT Monitoring of Neovascular AMD TreatmentWe discuss the use of a home based OCT system with artificial intelligence to monitor the treatment of neovascular AMD with Dr. Nancy Holekamp, Professor of Clinical Ophthalmology, Washington University School of Medicine.2022-05-2615 min
Foundation Fighting BlindnessEye on the Cure Podcast | Episode 20: Dr. Nancy HolekampMarch 11, 2022. Dr. Nancy Holekamp, a retinal specialist, clinical trial investigator, and key opinion leader in the retinal disease space, discusses new therapies and research for wet and dry age-related macular degeneration and some emerging treatment approaches for inherited retinal diseases.
This episode is sponsored by Apellis Pharmaceuticals.2022-03-1122 min
New Retina Radio by EyetubeAnti-VEGF, A Biography: Part 3This story started in the early days of VEGF's isolation in the 1970s and brought us to the discovery of ranibizumab and bevacizumab in the mid 2000s. The data revealed at the ASRS meeting in 2005 would change retina forever-and usher in a new competitor with a chance to disrupt the landscape yet again. Don't miss the final episode of this fascinating and important story told by those that lived it. We're bringing back some of the voices you've heard before, and some new ones, too. John D. Pitcher III, MD, invites Bob Avery, MD; David Brown, MD; Jeffrey Heier...2022-02-2434 minNew Retina Radio by EyetubeASRS 2021: The Pipeline for Wet AMD and GAThe pipeline in retina is bursting! Which datasets shared at the ASRS 2021 meeting provided insights into the future of retina? Mark Barakat, MD, joins the podcast to discuss topline results from a study examining the suprachoroidal delivery of RGX-314 (RegenxBio). And Nancy Holekamp, MD, stops by to educate us on the potential for targeting C1q in the complement cascade in patients with geographic atrophy. What’s the latest with the phase 2 ARCHER study? Find out on this episode.This editorially independent podcast is supported with advertising.2021-11-0519 minMedEdTalks - OphthalmologyPort Delivery System With Ranibizumab, With Nancy M. Holekamp, MD, and Arshad M. Khanani, MD, MAIn this podcast, expert clinicians will discuss best practices regarding the use of Port Delivery System with ranibizumab.2021-07-0118 minMedEdTalks - OphthalmologyAchieving Vascular Stability through Inhibition of Ang-2 in AMD and DME, With Nancy M. Holekamp, MD, and Carl D. Regillo, MD, FACSIn this podcast, expert clinicians will discuss achieving vascular stability through inhibition of Ang-2. To obtain CME credit, go here: https://tinyurl.com/y58538ef 2021-07-0118 minMedEdTalks - OphthalmologyEmerging Delivery Systems in Neovascular Retinal Disease: Focus on Gene Therapy, With Nancy M. Holekamp, MD, and Arshad M. Khanani, MD, MAIn this podcast, expert clinicians will discuss emerging gene therapies for AMD and DME. To obtain CME credit, go here: https://tinyurl.com/yusxpn44 2021-06-3019 minMedEdTalks - OphthalmologyEmerging Delivery Systems in Neovascular Retinal Disease: Focus on Devices, With Nancy M. Holekamp, MD, and Carl D. Regillo, MD, FACSIn this podcast, expert clinicians will discuss emerging delivery system devices in neovascular retinal disease. To obtain CME credit, please go here: https://tinyurl.com/thma9fwp2021-06-3015 minNew Retina Radio by EyetubeARCHWAY at AAOThe Port Delivery System With Ranibizumab (Genentech) is under investigation for the treatment of wet AMD in the phase 3 ARCHWAY trial, data from which was shared at this year’s AAO Annual Meeting. Nancy Holekamp, MD, sits down with NRR to provide a primary analysis of the results of ARCHWAY and discusses safety outcomes. This editorially independent podcast is supported with advertising.2020-11-1814 min
Straight From The Cutter's Mouth: A Retina PodcastEpisode 262: Strategies for Treating Wet Age-Related Macular Degeneration and more with Dr. Nancy HolekampDr. Nancy Holekamp joins the program to discuss her career development, the paradigm shift in terms of management of persistent subretinal fluid in wet age-related macular degeneration, strategies for improving AMD treatment including the port-delivery system and gene therapy, and her role in founding Women in Retina (WinR).Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Dorc, Oxurion, and Regeneron. Dr. Holekamp has received consulting fees from Allergan, Acucela, Apellis, Lineage Cell Therapeutics, Clearside Biosciences, Gemini, Genentech, Gyroscope, Katalyst Surgical, Nacuity, Notal Vision, Novartis, Polyactiva, and Regeneron. She is on the Speaker's...2020-10-1500 minMedEdTalks - OphthalmologyDosing Schedules for Emerging Agents Used to Treat nAMD That Require Less Frequent Dosing Than Standard Anti-VEGF TherapyIntravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. In this podcast, Dr. Arshad Khanani and Dr. Nancy Holekamp discuss dosing schedules for emerging agents in t...2020-07-2917 minMedEdTalks - OphthalmologyDosing Schedules for Current Agents Used to Treat Neovascular Age-Related Macular Degeneration (nAMD)Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. In this podcast, Dr. Arshad Khanani and Dr. Nancy Holekamp discuss dosing schedules for current anti-VEGF agents u...2020-07-2914 minMedEdTalks - OphthalmologyDrug Delivery in Neovascular Retinal DiseaseIn this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Nancy M. Holekamp, MD, discuss delivery systems for neovascular retinal diseases, with a particular focus on age-related macular degeneration. Transcript: https://bit.ly/2PqSj5P To obtain CME credit, please go here: https://bit.ly/2mNmJVt2019-09-2916 minNew Retina Radio by EyetubeAnti-VEGF, A Biography: Part 3This story started in the early days of VEGF's isolation in the 1970s and brought us to the discovery of ranibizumab and bevacizumab in the mid 2000s. The data revealed at the ASRS meeting in 2005 would change retina forever-and usher in a new competitor with a chance to disrupt the landscape yet again.Don't miss the final episode of this fascinating and important story told by those that lived it. We're bringing back some of the voices you've heard before, and some new ones, too. John D. Pitcher III, MD, invites Bob Avery, MD...2018-06-1534 min
As Seen From Here04-03-2005 As Seen From HereSubject: Intravitreal Steroid Implants for Choroidal Neovascularization
Paper Discussed: Holekamp NM, Thomas MA, Pearson A
The safety profile of long-term, high-dose intraocular corticosteroid delivery
American Journal of Ophthalmology, Mar 2005, 139(3) p421-8
Guest: Nancy Holekamp, MD
Associate Professor of Clinical Ophthalmology
Department of Ophthalmology and Visual Sciences
Washington University School of Medicine2005-04-0322 min